Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

被引：0

作者：

Mara Persano

Margherita Rimini

Toshifumi Tada

Goki Suda

Shigeo Shimose

Masatoshi Kudo

Jaekyung Cheon

Fabian Finkelmeier

Ho Yeong Lim

Lorenza Rimassa

José Presa

Gianluca Masi

Changhoon Yoo

Sara Lonardi

Francesco Tovoli

Takashi Kumada

Naoya Sakamoto

Hideki Iwamoto

Tomoko Aoki

Hong Jae Chon

Vera Himmelsbach

Tiziana Pressiani

Takumi Kawaguchi

Margarida Montes

Caterina Vivaldi

Caterina Soldà

Fabio Piscaglia

Atsushi Hiraoka

Takuya Sho

Takashi Niizeki

Naoshi Nishida

Christoph Steup

Massimo Iavarone

Giovanni Di Costanzo

Fabio Marra

Mario Scartozzi

Emiliano Tamburini

Giuseppe Cabibbo

Francesco Giuseppe Foschi

Marianna Silletta

Masashi Hirooka

Kazuya Kariyama

Joji Tani

Masanori Atsukawa

Koichi Takaguchi

Ei Itobayashi

Shinya Fukunishi

Kunihiko Tsuji

Toru Ishikawa

Kazuto Tajiri

机构：

[1] University Hospital of Cagliari,Medical Oncology

[2] IRCCS San Raffaele Hospital,Department of Medical Oncology

[3] Japanese Red Cross Himeji Hospital,Department of Internal Medicine

[4] Hokkaido University,Department of Gastroenterology and Hepatology, Graduate School of Medicine

[5] Kurume University School of Medicine,Division of Gastroenterology, Department of Medicine

[6] Kindai University Faculty of Medicine,Department of Gastroenterology and Hepatology

[7] CHA University School of Medicine,Department of Medical Oncology, CHA Bundang Medical Center

[8] University Hospital Frankfurt,Department of Internal Medicine 1

[9] Goethe University,Department of Medicine, Samsung Medical Center, School of Medicine

[10] Sungkyunkwan University,Department of Biomedical Sciences

[11] Humanitas University,Unit of Medical Oncology 2

[12] Humanitas Cancer Center,Department of Translational Research and New Technologies in Medicine and Surgery

[13] IRCCS Humanitas Research Hospital,Department of Oncology, ASAN Medical Center

[14] Liver Unit-CHTMAD,Oncology Unit 1

[15] University Hospital of Pisa,Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases

[16] University of Pisa,Department of Nursing

[17] University of Ulsan College of Medicine,Gastroenterology Center

[18] Veneto Institute of Oncology IOV-IRCCS,Division of Gastroenterology and Hepatology

[19] IRCCS Azienda Ospedaliero-Universitaria di Bologna,Dipartimento di Medicina Sperimentale e Clinica

[20] Gifu Kyoritsu University,Department of Oncology and Palliative Care, Cardinale G Panico

[21] Ehime Prefectural Central Hospital,Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE

[22] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano,Department of Internal Medicine

[23] Department of Hepatology,Division of Medical Oncology

[24] Università di Firenze,Department of Gastroenterology and Metabology

[25] Tricase City Hospital,Department of Gastroenterology

[26] University of Palermo,Department of Gastroenterology and Hepatology

[27] Ospedale per gli Infermi di Faenza,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[28] Policlinico Universitario Campus Bio-Medico,Department of Hepatology

[29] Ehime University Graduate School of Medicine,Department of Gastroenterology

[30] Okayama City Hospital,Department of Gastroenterology

[31] Kagawa University,Center of Gastroenterology

[32] Nippon Medical School,Department of Gastroenterology

[33] Kagawa Prefectural Central Hospital,Department of Gastroenterology

[34] Asahi General Hospital,Hepato

[35] Osaka Medical and Pharmaceutical University,biliary Center

[36] Teine Keijinkai Hospital,Department of Gastroenterology and Hepatology

[37] Saiseikai Niigata Hospital,Department of Gastroenterology

[38] Toyama University Hospital,Division of Gastroenterology and Hepatology, Department of Internal medicine

[39] Japanese Red Cross Matsuyama Hospital,Department of Gastroenterology

[40] Ogaki Municipal Hospital,Department of Clinical Research

[41] Japanese Red Cross Takamatsu Hospital,Division of Gastroenterology and Hepatology

[42] Hyogo Medical University,Department of Hepatology

[43] Gunma Saiseikai Maebashi Hospital,Department of Surgery

[44] National Hospital Organization Takasaki General Medical Center,Department of Gastroenterology

[45] Otakanomori Hospital,Drug Development Unit

[46] Hamamatsu University School of Medicine,Department of Oncology

[47] Kansai Medical University,undefined

[48] National Hospital Organization Takasaki General Medical Center,undefined

[49] Sarah Cannon Research Institute UK,undefined

[50] IRCCS San Raffaele Scientific Institute Hospital,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷

关键词：

Advanced HCC; Atezolizumab plus bevacizumab; First-line therapy; Lenvatinib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：5591 / 5602

页数：11

共 50 条

[21] COMPARISON EFFICACY AND SAFETY BETWEEN ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB AS FIRST-LINE SYSTEMIC THERAPY FOR HEPATOCELLULAR CARCINOMA: A REAL-WORLD STUDY
Boonkaya, Sangdao
Thanapirom, Kessarin
Siripon, Nipaporn
Thaimai, Panarat
Ananchuensook, Prooksa
Sriphoosanaphan, Supachaya
Tanasanvimon, Surbpong
Treeprasertsuk, Sombat
Komolmit, Piyawat
GASTROENTEROLOGY, 2024, 166 (05) : S73 - S74
[22] Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
Shen, Xiao
Zhang, Jin-Xing
Liu, Jin
Liu, Sheng
Shi, Hai-Bin
Cheng, Yuan
Zhang, Qing-Qiao
Yin, Guo-Wen
Zu, Qing-Quan
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1993 - 2003
[23] Clinical outcomes and response (R) with atezolizumab plus bevacizumab (AB) or lenvatinib (L) in hepatocellular carcinoma (HCC)
Persano, M.
Rimini, M.
Cascinu, S.
Scartozzi, M.
Gardini, A. Casadei
ANNALS OF ONCOLOGY, 2022, 33 : S1459 - S1459
[24] Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice
Nakagawa, Miyuki
Inoue, Masanori
Ogasawara, Sadahisa
Maruta, Susumu
Okubo, Tomomi
Itokawa, Norio
Iino, Yotaro
Obu, Masamichi
Haga, Yuki
Seki, Atsuyoshi
Kikuchi, Yasuharu
Kogure, Tadayoshi
Yumita, Sae
Ishino, Takamasa
Ogawa, Keita
Fujiwara, Kisako
Iwanaga, Terunao
Fujita, Naoto
Sakuma, Takafumi
Kojima, Ryuta
Kanzaki, Hiroaki
Koroki, Keisuke
Taida, Takashi
Kobayashi, Kazufumi
Kiyono, Soichiro
Nakamura, Masato
Kanogawa, Naoya
Kondo, Takayuki
Nakagawa, Ryo
Nakamoto, Shingo
Muroyama, Ryosuke
Chiba, Tetsuhiro
Itobayashi, Ei
Atsukawa, Masanori
Koma, Yoshihiro
Azemoto, Ryosaku
Ito, Kenji
Mizumoto, Hideaki
Shinozaki, Masami
Kato, Jun
Kato, Naoya
CANCER, 2023, 129 (04) : 590 - 599
[25] Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world
Zhang, Junwei
Fang, Jinyu
Xun, Ziyu
Xu, Yiyao
Lu, Xin
Zhao, Haitao
HEPATOLOGY, 2022, 76 (04) : E84 - E85
[26] Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort
Jost-Brinkmann, Fabian
Demir, Muenevver
Wree, Alexander
Luedde, Tom
Loosen, Sven H.
Mueller, Tobias
Tacke, Frank
Roderburg, Christoph
Mohr, Raphael
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (11) : 1313 - 1325
[27] Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
Ando, Yuwa
Kawaoka, Tomokazu
Kosaka, Masanari
Shirane, Yuki
Johira, Yusuke
Miura, Ryoichi
Murakami, Serami
Yano, Shigeki
Amioka, Kei
Naruto, Kensuke
Kosaka, Yumi
Uchikawa, Shinsuke
Kodama, Kenichiro
Fujino, Hatsue
Nakahara, Takashi
Ono, Atsushi
Murakami, Eisuke
Yamauchi, Masami
Okamoto, Wataru
Takahashi, Shoichi
Imamura, Michio
Chayama, Kazuaki
Aikata, Hiroshi
CANCERS, 2021, 13 (16)
[28] Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Yuka Hayakawa
Kaoru Tsuchiya
Masayuki Kurosaki
Yutaka Yasui
Shun Kaneko
Yuki Tanaka
Shun Ishido
Kento Inada
Sakura Kirino
Koji Yamashita
Tsubasa Nobusawa
Hiroaki Matsumoto
Tatsuya Kakegawa
Mayu Higuchi
Kenta Takaura
Shohei Tanaka
Chiaki Maeyashiki
Nobuharu Tamaki
Hiroyuki Nakanishi
Jun Itakura
Yuka Takahashi
Yasuhiro Asahina
Ryuichi Okamoto
Namiki Izumi
Investigational New Drugs, 2022, 40 : 392 - 402
[29] Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis
D'Alessio, Antonio
Weinmann, Arndt
Galle, Peter R.
Fulgenzi, Claudia Angela Maria
Bettinger, Dominik
Bengsch, Bertram
Vogel, Arndt
Balcar, Lorenz
Scheiner, Bernhard
Navaid, Musharraf
Naqash, Abdul Rafeh
Personeni, Nicola
Pressiani, Tiziana
Sharma, Rohini
Pinter, Matthias
Cortellini, Alessio
Rimassa, Lorenza
Pinato, David James
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[30] Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Hayakawa, Yuka
Tsuchiya, Kaoru
Kurosaki, Masayuki
Yasui, Yutaka
Kaneko, Shun
Tanaka, Yuki
Ishido, Shun
Inada, Kento
Kirino, Sakura
Yamashita, Koji
Nobusawa, Tsubasa
Matsumoto, Hiroaki
Kakegawa, Tatsuya
Higuchi, Mayu
Takaura, Kenta
Tanaka, Shohei
Maeyashiki, Chiaki
Tamaki, Nobuharu
Nakanishi, Hiroyuki
Itakura, Jun
Takahashi, Yuka
Asahina, Yasuhiro
Okamoto, Ryuichi
Izumi, Namiki
INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 392 - 402

← 1 2 3 4 5 →